AUTHOR=Rodrigues-da-Silva Rodrigo Nunes , Soares Isabela Ferreira , Lopez-Camacho Cesar , Martins da Silva João Hermínio , Perce-da-Silva Daiana de Souza , Têva Antônio , Ramos Franco Antônia Maria , Pinheiro Francimeire Gomes , Chaves Lana Bitencourt , Pratt-Riccio Lilian Rose , Reyes-Sandoval Arturo , Banic Dalma Maria , Lima-Junior Josué da Costa 

TITLE=Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants

JOURNAL=Frontiers in Immunology

VOLUME=8

YEAR=2017

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.00077

DOI=10.3389/fimmu.2017.00077

ISSN=1664-3224

ABSTRACT=<p>The cell-traversal protein for ookinetes and sporozoites (CelTOS), a highly conserved antigen involved in sporozoite motility, plays an important role in the traversal of host cells during the preerythrocytic stage of <italic>Plasmodium</italic> species. Recently, it has been considered an alternative target when designing novel antimalarial vaccines against <italic>Plasmodium falciparum</italic>. However, the potential of <italic>Plasmodium vivax</italic> CelTOS as a vaccine target is yet to be explored. This study evaluated the naturally acquired immune response against a recombinant <italic>P. vivax</italic> CelTOS (PvCelTOS) (IgG and IgG subclass) in 528 individuals from Brazilian Amazon, as well as the screening of B-cell epitopes <italic>in silico</italic> and peptide assays to associate the breadth of antibody responses of those individuals with exposition and/or protection correlates. We show that PvCelTOS is naturally immunogenic in Amazon inhabitants with 94 individuals (17.8%) showing specific IgG antibodies against the recombinant protein. Among responders, the IgG reactivity indexes (RIs) presented a direct correlation with the number of previous malaria episodes (<italic>p</italic> = 0.003; <italic>r</italic> = 0.315) and inverse correlation with the time elapsed from the last malaria episode (<italic>p</italic> = 0.031; <italic>r</italic> = −0.258). Interestingly, high responders to PvCelTOS (RI &gt; 2) presented higher number of previous malaria episodes, frequency of recent malaria episodes, and ratio of cytophilic/non-cytophilic antibodies than low responders (RI &lt; 2) and non-responders (RI &lt; 1). Moreover, a high prevalence of the cytophilic antibody IgG1 over all other IgG subclasses (<italic>p</italic> &lt; 0.0001) was observed. B-cell epitope mapping revealed five immunogenic regions in PvCelTOS, but no associations between the specific IgG response to peptides and exposure/protection parameters were found. However, the epitope (PvCelTOS<sub>I136-E143</sub>) was validated as a main linear B-cell epitope, as 92% of IgG responders to PvCelTOS were also responders to this peptide sequence. This study describes for the first time the natural immunogenicity of PvCelTOS in Amazon individuals and identifies immunogenic regions in a full-length protein. The IgG magnitude was mainly composed of cytophilic antibodies (IgG1) and associated with recent malaria episodes. The data presented in this paper add further evidence to consider PvCelTOS as a vaccine candidate.</p>